| ZIOPHARM Oncology is a biopharmaceutical company focused on discovering, developing and commercializing immuno-oncology platforms that utilize cell- and gene-based therapies to treat patients with cancer. Co.'s primary platform is referred to as Sleeping Beauty and is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that is intended to stably engineer T cells outside of the body for subsequent infusion. Co.'s second platform is referred to as Controlled IL-12 and is designed to stimulate expression of interleukin 12, a master regulator of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. We show 49 historical shares outstanding datapoints in our coverage of ZIOP's shares outstanding history.|
Understanding the changing numbers of ZIOP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ZIOP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ZIOP by allowing them to research ZIOP shares outstanding history
as well as any other stock in our coverage universe.